Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus paclitaxel-platinum with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer
CTR20222087Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of QL1706 in Cervical Cancer (CC), sponsored by Qilu Pharmaceutical. Started Sep 2022; status: completed.
02
Drugs
QL1706
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20222087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222087.